CN201320317Y - Hybrid biological artificial liver extracorporeal supporting device - Google Patents
Hybrid biological artificial liver extracorporeal supporting device Download PDFInfo
- Publication number
- CN201320317Y CN201320317Y CNU200820238139XU CN200820238139U CN201320317Y CN 201320317 Y CN201320317 Y CN 201320317Y CN U200820238139X U CNU200820238139X U CN U200820238139XU CN 200820238139 U CN200820238139 U CN 200820238139U CN 201320317 Y CN201320317 Y CN 201320317Y
- Authority
- CN
- China
- Prior art keywords
- pump
- end connects
- blood
- plasma
- artificial liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The utility model relates to a hybrid biological artificial liver extracorporeal supporting device which can temporarily replace human liver function. The structure of the extracorporeal supporting device comprises: a bioreactor in an incubator is connected with a reactor circulating pump and a membrane lung which is connected with an exchange column; the exchange column is connected with the reactor circulating pump; a blood pump is connected with a blood inlet and a separating tube; a plasma perfusion pump is connected with a three-way pipe and an active carbon adsorption column; a biological artificial liver pump is connected with the active carbon adsorption column and the exchanging column; a dialysis pump is connected with the exchange column and a dialysis tube; the separating tube is connected with a blood pool and the three-way pipe; the three-way pipe is connected with a waste plasma tank and the plasma perfusion pump; the active carbon adsorption column is connected with the biological artificial liver pump; the dialysis tube is connected with the blood pool, a dialysis liquid bag and a waste liquid tank; the blood pool is connected with a blood outlet. The hybrid biological artificial liver extracorporeal supporting device solves the respective defects of the non-biological artificial liver and the biological artificial liver, causes the organic combination of non-biological artificial liver and the biological artificial liver, generates synergistic action and realizes plasma exchange, plasma perfusion, biological artificial liver and hemodialysis.
Description
Technical field
This utility model relates to a kind of armarium, particularly a kind of temporary transient mixed biology artificial liver vitro supporting device that substitutes human liver's function.
Background technology
The artificial liver device can be the patient of short duration liver function support is provided, and is effective auxiliary treatment means of diseases such as present liver failure, has a good application prospect.
Before the present utility model, the artificial liver device mainly is divided into abiotic artificial liver and bioartificial liver's two big classes.
Abiotic artificial liver develop at present comparative maturity, its artificial liver device commonly used has following several: plasmapheresis, blood plasma perfusion absorption, hemodialysis and hemofiltration device etc.The plasmapheresis device is by the separating plasma technology, cell component in the blood samples of patients and plasma fraction are separated, with the latter with the displacement of human normal plasma or plasma substitute, thereby remove the liver toxic component in the blood plasma in patient's body that declines, its shortcoming is that expense is expensive and easily cause the blood plasma waste.The blood plasma device for casting is meant blood plasma by extracorporeal circulation, be incorporated in the container that adsorbent (resin or active carbon) is housed, with some endogenous of adsorption removal or exogenous poisonous substance, as bilirubin etc., its shortcoming is that adsorption process does not have selectivity, when removing toxicant, a lot of useful active component in the blood plasma also is adsorbed.Haemodialysis equipment be with blood and dialysis solution in the semipermeable membrane both sides mode by disperse carry out mass exchange, thereby remove the liver micromolecular material in some that declines in patient's body, as carbamide, creatinine etc., regulate water balance by the mode of ultrafiltration simultaneously, environment in stable, but this device can only be removed the liver part toxin in patient's body that declines, and is invalid to some macromolecular substances.
Though above-mentioned various abiotic artificial liver can be removed toxin to a certain extent, all can not replenish needed various active substances in patient's body constantly, can't finish the function and the effect of artificial liver device truly.
The appearance of bioartificial liver devices has remedied this defective.Bioartificial liver devices mainly is by cultivating the external source hepatocyte of high vigor in reactor, simulating the device of liver function in the normal human.Bioartificial liver devices also has multiple biological functions such as synthetic, metabolism, conversion except function of detoxification, can realize liver replacement therapy truly, but the technology of bioartificial liver devices is still immature at present, also is in the exploratory stage.And, if the decline toxin and the hepatocyte in metabolite and the bioreactor of a large amount of accumulation in patient's body of liver are directly carried out mass exchange, probably can cause the rapid forfeiture of hepatocyte activity and function, influence the performance of bio-artificial liver function.
Summary of the invention
The purpose of this utility model just is to overcome the defective that above-mentioned abiotic artificial liver and bioartificial liver exist separately, designs, develops a kind of mixed biology artificial liver vitro supporting device.
The technical solution of the utility model is:
Mixed biology artificial liver vitro supporting device, upper left quarter is the incubator control knob in the shell, upper right quarter is an incubator, its major technique is characterised in that bioreactor is set in the incubator, bioreactor one end coupled reaction device circulating pump, the other end connects membrane lung, and the membrane lung other end connects exchange column, exchange column other end coupled reaction device circulating pump; The shell mid portion is provided with blood pump, its front pump one end connects the blood inlet, the other end connects separator tube, plasma perfusion pump one end connects threeway, the other end connects active carbon adsorption column, and bioartificial liver's pump one end connects active carbon adsorption column, and the other end connects exchange column, dialysate pump one end connects exchange column, and the other end connects Dialysis tubing; The bottom is provided with heparin pump in the shell, the separator tube other end connects blood pool, and the blood pool other end connects threeway, and threeway two ends in addition connects discarded blood plasma jar, plasma perfusion pump respectively, active carbon adsorption column one end connects the plasma perfusion pump, and the other end connects bioartificial liver's pump; Dialysis tubing one end connects dialysate pump, and the other end connects blood pool, two side openings on the Dialysis tubing, wherein a side opening connects dialyzate bag, another side opening connects discarded flow container, and blood pool one end connects plasma bags, separating plasma pipe and Dialysis tubing, and the blood pool other end connects the blood outlet.
Advantage of the present utility model and effect are organic and dexterously abiotic artificial liver device and bioartificial liver devices are combined, avoid the two defective separately, make it to bring into play the advantage of abiotic artificial liver device, bring into play the advantage of artificial liver device again, and make the two performance synergism that combines; Simultaneously, the combination of the two makes bioartificial liver devices obtain practical application.
Mixed biology artificial liver vitro supporting device of the present utility model has simple in structure, reliable, is easy to realize, and is easy to operate.
Advantage of the present utility model is specific as follows:
1, modes such as plasmapheresis, plasma perfusion, bioartificial liver, hemodialysis is integrated into a machine.
When 2, mixed biology artificial liver is used in combination, at first carry out preliminary detoxifcation, avoided in the blood plasma noxious substance hepatocellular toxic action among the bioartificial liver of back by plasmapheresis and plasma perfusion.
When 3, mixed biology artificial liver was used in combination, functions such as the secretion by the bioartificial liver, synthetic, metabolism had been replenished the useful active component that is lost by the front activated carbon adsorption in the blood plasma.
When 4, mixed biology artificial liver was used in combination, last hemodialysis had guaranteed blood behind the various artificial liver devices through the front, still can keep good fluid and electrolyte balance to get back in the human body, and can further remove small-molecule substances such as carbamide and creatinine.
5, be provided with membrane lung in the bioartificial liver loop that this utility model adopted, and in culture fluid, added erythrocyte, solve hepatocellular oxygen confession problem in the reactor thereby take oxygen by erythrocyte.
Other advantage of the present utility model and effect will go on to say below.
Description of drawings
Fig. 1---structural principle sketch map of the present invention.
The right view of Fig. 2---Fig. 1.
The left view of Fig. 3---Fig. 1.
The specific embodiment
Brief summary of the invention of the present utility model is as follows:
1. plasmapheresis: the plasmapheresis parts comprise front pump, heparin pump, plasma separator, plasma bags, discarded blood plasma jar and blood pool, and the plasmapheresis parts are positioned at before the plasma perfusion parts.Blood directly abandons after telling blood plasma by plasma separator, and fresh plasma is replenished by the plasma bags synchronous same-speed.Remove the part noxious substance by plasmapheresis.
2. plasma perfusion: the plasma perfusion parts comprise hemoperfusion pump and bilirubin adsorption column, and active carbon is housed in the adsorption column, and the plasma perfusion parts are positioned at after the plasmapheresis parts, before bioartificial liver's parts.The blood plasma of being told by plasma separator adsorbs to fall bilirubin etc. by active carbon adsorption column.
3. bioartificial liver: bioartificial liver's parts comprise bioartificial liver's pump, bioreactor pump, membrane lung, bioreactor and exchange column.These elements are formed loops, are positioned at after the plasma perfusion parts, before the hemodialysis parts, and place the constant incubator of 37 ℃ and 5%CO2, to keep the best living environment of hepatocyte in it.Circulation has culture fluid in this loop, is mixed with erythrocyte in the culture fluid, carries out oxygenate during through membrane lung, and takes oxygen to hepatocyte, thereby guarantee that oxygen supplies.Culture fluid in this loop and the blood plasma in the blood circuit constitute two circulations, carry out mass exchange in exchange column, thereby have avoided immunoreactive generation.And by mass exchange, the toxic component in the blood plasma enters reactor, by the hepatocyte metabolism; And the excretory active substance of hepatocyte enters blood plasma, and additional plasma perfusion adsorbs the active component that falls.
4. hemodialysis: the hemodialysis parts comprise dialysate pump, Dialysis tubing, dialyzate bag and discarded liquid bag, and the hemodialysis parts are positioned at after bioartificial liver's parts.Blood plasma is further removed small-molecule substances such as carbamide, creatinine in Dialysis tubing, and after regulating water-electrolyte balance, returns in patient's body.
Be concrete implementation content of the present utility model below:
As Fig. 1, Fig. 2, shown in Figure 3:
Upper left quarter in this utility model shell 21 is a control knob 22, the temperature in the control upper right quarter incubator 23, oxygen concentration, gas concentration lwevel etc.; In the incubator 23 of upper right quarter, be provided with bioreactor 11, bioreactor 11 1 end coupled reaction device circulating pumps 12, the other end connects membrane lung 10, and membrane lung 10 other ends connect exchange column 9, and exchange column 9 is also distinguished coupled reaction device circulating pump 12, dialysate pump 13, bioartificial liver's pump 8; Mid portion is provided with blood pump in the shell 21, and wherein front pump 2 one ends connect blood inlet 1, and the other end connects separator tube 4, and separator tube 4 two ends in addition connects blood pool 17, threeway 5 respectively, and threeway 5 two ends in addition connects discarded blood plasma jar 18, plasma perfusion pump 6 respectively; Plasma perfusion pump 6 other ends connect active carbon adsorption column 7, and active carbon adsorption column 7 other ends connect bioartificial liver's pump 8, and dialysate pump 13 other ends connect Dialysis tubing 14; The bottom is provided with heparin pump 3 in the shell 21, and Dialysis tubing 14 other ends connect blood pool 17, two side openings on the Dialysis tubing 14, and one of them side opening connects dialyzate bag 16, and another side opening connects discarded flow container 19; Blood pool 17 connects plasma bags 15, separator tube 4, Dialysis tubing 14 and blood outlet 20 respectively.
Concrete application of the present utility model:
1, part plasmapheresis
Before using threeway 5 is threaded to the 5a position.Blood is pumped into through front pump 2 by blood inlet 1, enters separator tube 4 after heparin pump 3 heparinizations, and isolated blood plasma is through entering discarded blood plasma jar 18 after the threeway 5; Fresh plasma enters blood pool 17 by plasma bags 15 synchronous same-speeds, after separator tube 4 isolated erythrocyte mix, gets back in the body through blood outlet 20.In this course, fresh plasma replenishes speed and poisonous blood plasma, and to abandon speed identical, reaches by plasmapheresis and remove part noxious substance purpose.
2, plasma perfusion:
After part plasmapheresis step finishes, continue separated plasma, plasma perfusion pump 6 falls bilirubin etc. with isolating blood plasma by active carbon adsorption column 7 absorption with in the blood plasma pump people active carbon adsorption column 7, further removes the noxious substance in the blood plasma.
3, bioartificial liver:
Blood plasma is after active carbon adsorption column 7 detoxifcations, enter bioartificial liver devices, in exchange column 9 with bioreactor 11 in the excretory active substance of hepatocyte carry out mass exchange, finish hepatocellular secretion, metabolism, function such as synthetic, thereby replenish the active component that is adsorbed in the plasma perfusion step.
4, hemodialysis:
Blood plasma enters Dialysis tubing 14 dialysis through behind the bioartificial liver, further removes small-molecule substances such as carbamide, creatinine, and regulates water-electrolyte balance, thereby guarantee the stable of patient's homeostasis.Blood plasma mixes with erythrocyte through behind the Dialysis tubing 14, gets back in patient's body through blood outlet 20.
The concrete steps in the 2nd～4 step are:
Threeway 5 is threaded to the 5b position.Blood is pumped into through front pump 2 by blood inlet 1, after heparin pump 3 heparinizations, enter separator tube 4, isolated blood plasma then enters plasma perfusion pump 6 through after the threeway 5, be pumped to active carbon adsorption column 7, behind adsorpting detoxication by bioartificial liver's pump 8 pumps to exchange column 9, culture fluid in the bioreactor 11 is pumped into exchange column 9 by reactor cycles pump 12 behind membrane lung 10 oxygenates, both carry out mass exchange in exchange column 9 after, blood plasma flow out by exchange column 9 and by dialysate pump 13 pumps to Dialysis tubing 14; Fresh dialysis fluid enters Dialysis tubing 14 by bag filter 16, and the waste liquid after the dialysis then enters into discarded flow container 19; Blood plasma enters blood pool 17 after dialysis, after isolated erythrocyte mixes, get back in the body through blood outlet 20.
In this utility model, increase an exchange column 9 in the bioartificial liver loop, thereby carry out mass exchange, avoided immunoreactive generation by bicirculating mode.
Hence one can see that, and this utility model is that abiotic artificial liver and bioartificial liver devices are organically combined, and produces synergism, obtains good effect.
Claims (2)
1. mixed biology artificial liver vitro supporting device, upper left quarter is the incubator control knob in the shell, upper right quarter is an incubator, it is characterized in that being provided with in the incubator bioreactor, bioreactor one end coupled reaction device circulating pump, the other end connects membrane lung, and the membrane lung other end connects exchange column, exchange column other end coupled reaction device circulating pump; The shell mid portion is provided with blood pump, its front pump one end connects the blood inlet, the other end connects separator tube, plasma perfusion pump one end connects threeway, the other end connects active carbon adsorption column, and bioartificial liver's pump one end connects active carbon adsorption column, and the other end connects exchange column, dialysate pump one end connects exchange column, and the other end connects Dialysis tubing; The bottom is provided with heparin pump in the shell, the separator tube other end connects blood pool, and the blood pool other end connects threeway, and threeway two ends in addition connects discarded blood plasma jar, plasma perfusion pump respectively, active carbon adsorption column one end connects the plasma perfusion pump, and the other end connects bioartificial liver's pump; Dialysis tubing one end connects dialysate pump, and the other end connects blood pool, two side openings on the Dialysis tubing, wherein a side opening connects dialyzate bag, another side opening connects discarded flow container, and blood pool one end connects plasma bags, separating plasma pipe and Dialysis tubing, and the blood pool other end connects the blood outlet.
2. mixed biology artificial liver vitro supporting device according to claim 1 is characterized in that bioreactor places 37 ℃ and 5%CO
2Constant incubator in.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU200820238139XU CN201320317Y (en) | 2008-12-26 | 2008-12-26 | Hybrid biological artificial liver extracorporeal supporting device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU200820238139XU CN201320317Y (en) | 2008-12-26 | 2008-12-26 | Hybrid biological artificial liver extracorporeal supporting device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201320317Y true CN201320317Y (en) | 2009-10-07 |
Family
ID=41157706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNU200820238139XU Expired - Fee Related CN201320317Y (en) | 2008-12-26 | 2008-12-26 | Hybrid biological artificial liver extracorporeal supporting device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201320317Y (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018109070A1 (en) * | 2016-12-15 | 2018-06-21 | Fresenius Medical Care Deutschland Gmbh | System for extracorporeal blood treatment, treatment apparatus, kit and method for operating a system for extracorporeal blood treatment |
| US20210030943A1 (en) * | 2018-02-01 | 2021-02-04 | Southern Medical University Zhujiang Hospital | Combined Bio-Artificial Liver Support System |
| CN112604048A (en) * | 2020-12-04 | 2021-04-06 | 广东乾晖生物科技有限公司 | Special pipeline for total-liver type bioartificial liver support system |
-
2008
- 2008-12-26 CN CNU200820238139XU patent/CN201320317Y/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018109070A1 (en) * | 2016-12-15 | 2018-06-21 | Fresenius Medical Care Deutschland Gmbh | System for extracorporeal blood treatment, treatment apparatus, kit and method for operating a system for extracorporeal blood treatment |
| CN110072569A (en) * | 2016-12-15 | 2019-07-30 | 费森尤斯医疗护理德国有限责任公司 | For the system of extracorporeal blood treatment, processing equipment, the operating method of external member and the system for extracorporeal blood treatment |
| US11433173B2 (en) | 2016-12-15 | 2022-09-06 | Fresenius Medical Care Deutschland Gmbh | System for extracorporeal blood treatment, treatment apparatus, kit and method for operating a system for extracorporeal blood treatment |
| US20210030943A1 (en) * | 2018-02-01 | 2021-02-04 | Southern Medical University Zhujiang Hospital | Combined Bio-Artificial Liver Support System |
| US11911552B2 (en) * | 2018-02-01 | 2024-02-27 | Southern Medical University Zhujiang Hospital | Combined bio-artificial liver support system |
| CN112604048A (en) * | 2020-12-04 | 2021-04-06 | 广东乾晖生物科技有限公司 | Special pipeline for total-liver type bioartificial liver support system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105120913B (en) | Sodium and buffer solution source capsule for the controlled compatible stream of modularization | |
| CN104994894B (en) | The sodium management system of haemodialysis | |
| US7338461B2 (en) | Modified organ support devices | |
| Sauer et al. | Modular extracorporeal liver support | |
| CN107252505A (en) | The system and method controlled for multi-functional volume fluid | |
| CN103263704B (en) | Be equipped with the plasmapheresis absorption filtration cleaning system of slurry storing bag | |
| CN108430529A (en) | system and method for extracorporeal blood treatment | |
| AU2016356067B2 (en) | Method for extracorporeal carbon dioxide removal | |
| CN109069719B (en) | System or apparatus and method for conducting dialysis | |
| CN201033178Y (en) | Novel external artificial liver supporting and treating system | |
| CN104958795B (en) | Whole blood perfusion bioartificial liver system | |
| EP2076297A2 (en) | Fluid-conserving cascade hemofiltration | |
| CN201123923Y (en) | Mixed type artificial liver system capable of for curing multiple-organ dysfunctional syndrome | |
| CN201320317Y (en) | Hybrid biological artificial liver extracorporeal supporting device | |
| CN101455864B (en) | Mixed biology artificial liver vitro supporting device | |
| CN2810611Y (en) | In-vitro artificial liver support system | |
| KR20150070922A (en) | Continous Recycle Typed Dialysis System for Portable Artifical Kidney | |
| Kim et al. | Effects of dialysate flow configurations in continuous renal replacement therapy on solute removal: computational modeling | |
| de Francisco et al. | Hemodiafiltration with on-line endogenous reinfusion | |
| RU93276U1 (en) | EXTRACORPORAL BLOOD CLEANING DEVICE | |
| CN2824949Y (en) | An in-vitro molecule-absorbing circulating system | |
| CN1879900A (en) | In vitro molecular adsorption and circulation system | |
| CN104524653A (en) | Artificial liver and blood purification system | |
| CN203280813U (en) | Plasma exchange absorption filtering purifying system provided with plasma storage bag in matched mode | |
| AU2018387643B2 (en) | Dialysis system having carbon dioxide generation and prime |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091007 Termination date: 20121226 |